Please select the option that best describes you:

Topics: Breast Cancer • Head and Neck Cancers • Gastrointestinal Cancers • Genitourinary Cancers • Melanoma/Skin Cancer • Thoracic Malignancies • Medical Oncology • Immunotherapy

How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?

See https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.8516 and https://morningsidecenter.emory.edu/promising-therapies/blogs/immunotherapy_chemo.html citing some evidence.